Contracts › 75N91022F00001
75N91022F00001: Vrc Hiv Mab-Research, Development, and Production to Support Hiv Monoclonal Antibody Development - the Primary Objective Is to Support Cell Line Development, Process Development, Analytical Development, Reagent Production, Manufacturing, and Testing
Awarded to Leidos Biomedical Research Inc by National Institutes of Health (NIH).
$19.1Mobligated
$19.4Mpotential value
15 September 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N91022F00001 |
|---|---|
| Vehicle | 75N91019D00024 |
| Awardee | Leidos Biomedical Research Inc |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NIH NCI |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | MD |
| Period of performance | 01 February 2022 to 15 September 2027 |
| Potential end | 15 September 2027 |
| Estimated recompete solicitation | ~Q1 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 06 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record